^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AVENIO Tumor Tissue Expanded Kit

    Company:
    Roche
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    over2years
    DIFFERENT MUTATIONS IN PATIENTS WITH PRIMARY LARGE B-CELL LYMPHOMA (EHA 2022)
    According to the bioinformatics analysis, FGF/FGFR3 was the most significant signaling pathway for PMBCL in our study, because it is able to activate all listed pathways via FGFR-receptor activation. Conclusion NGS revealed clinically significant mutations in the genes in patients with PMBCL, the therapeutic potential of which requires the further studies.
    Clinical
    |
    ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR3 (Fibroblast growth factor receptor 3) • RNF43 (Ring Finger Protein 43) • PI3K (Phosphoinositide 3-kinases)
    |
    PIK3CA mutation • FGFR3 mutation • ALK mutation • EZH2 mutation • MET mutation • RNF43 mutation
    |
    AVENIO Tumor Tissue Expanded Kit
    over2years
    Newly identified molecular and genetic characteristics of primary mediastinal large B-cell lymphoma. (ASCO 2022)
    The identified polymorphisms and the relationship of mutated genes with PMBLC signaling paths can serve as new therapeutic targets for patients with PMBLC.
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • RNF43 (Ring Finger Protein 43) • CCND3 (Cyclin D3)
    |
    AVENIO Tumor Tissue Expanded Kit